Groowe Groowe BETA

US Stock Market News

Stay on top of the US stock market with real-time breaking news and market-moving stories. Our platform continuously aggregates updates from trusted financial news sources, giving traders and investors a fast overview of events that may impact stock prices.

Whether you're tracking specific companies or scanning the broader market, the news feed helps you quickly identify important developments as they happen.

Create an account to access the live news feed. Access is free while the platform is in beta. Visitors without an account can still browse the latest headlines with a 15-minute delay.

⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

October 13, 2026 Deadline: Join Class Action Lawsuit Against Aardvark Therapeutics, Inc. (AARD) - Contact Levi & Korsinsky

accessnewswire.com
AARD

Stockholder Alert: Robbins LLP Informs Investors of the XTI Aerospace, Inc. Class Action

businesswire.com
XTIA

LexinFintech Holdings Ltd. Reports Second Quarter 2026 Unaudited Financial Results

globenewswire.com
LX

Lost Money on Aardvark Therapeutics, Inc. (AARD)? Urged to Join Class Action Before October 13, 2026 - Contact Levi & Korsinsky

accessnewswire.com
AARD

Alnylam präsentiert auf dem ESC Congress 2026 neue Daten, die die Wirksamkeit des RNAi-basierten TTR-Silencing bei verschiedenen ATTR-CM-Patientengruppen und in verschiedenen Behandlungsumgebungen belegen

businesswire.com
ALNY

Alnylam présente de nouvelles données lors du congrès de l’ESC 2026, qui confirment l’efficacité de l’inhibition de la TTR par ARNi chez les populations de patients atteints d’ATTR-CM et dans différents contextes thérapeutiques

businesswire.com
ALNY

Alnylam presenta nuevos datos en el Congreso 2026 de la ESC que refuerzan la eficacia en el silenciamiento de la transtiretina mediante interferencia de ARN en poblaciones de pacientes y entornos de tratamiento de miocardiopatía amiloide por trans...

businesswire.com
ALNY

Alnylam presenta nuovi dati al Congresso ESC 2026, rafforzando l'efficacia del silenziamento della transtiretina (TTR) basato sulla tecnologia RNAi nelle popolazioni di pazienti affetti da ATTR-CM e nei diversi contesti terapeutici

businesswire.com
ALNY

Alnylam presenteert nieuwe gegevens op het ESC-congres 2026 en legt de nadruk op de effectiviteit van RNAi-gebaseerde TTR-silencing bij verschillende ATTR-CM-patiëntengroepen

businesswire.com
ALNY

October 13, 2026 Deadline Approaching: Join Class Action Against Aardvark Therapeutics, Inc. (AARD) - Contact Levi & Korsinsky

accessnewswire.com
AARD
View all news →